Business Description
Rain Oncology Inc
NAICS : 541714
SIC : 2834
ISIN : US75082Q1058
Description
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 169.56 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -39.4 | |||||
| 3-Year EPS without NRI Growth Rate | -38.4 | |||||
| 3-Year FCF Growth Rate | -28.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.97 | |||||
| 9-Day RSI | 49.34 | |||||
| 14-Day RSI | 53.89 | |||||
| 6-1 Month Momentum % | -11.03 | |||||
| 12-1 Month Momentum % | -87.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.58 | |||||
| Quick Ratio | 5.58 | |||||
| Cash Ratio | 5.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -50.4 | |||||
| Shareholder Yield % | -0.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.06 | |||||
| ROA % | -69.78 | |||||
| ROIC % | -2700.4 | |||||
| ROC (Joel Greenblatt) % | -13877.35 | |||||
| ROCE % | -85.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.65 | |||||
| Price-to-Tangible-Book | 0.65 | |||||
| EV-to-EBIT | 0.45 | |||||
| EV-to-Forward-EBIT | -4.46 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-FCF | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 0.66 | |||||
| Price-to-Net-Cash | 0.7 | |||||
| Earnings Yield (Greenblatt) % | 222.22 | |||||
| FCF Yield % | -149.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RAIN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rain Oncology Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.06 | ||
| Beta | 0 | ||
| Volatility % | 98.35 | ||
| 14-Day RSI | 53.89 | ||
| 14-Day ATR ($) | 0.028642 | ||
| 20-Day SMA ($) | 1.2095 | ||
| 12-1 Month Momentum % | -87.9 | ||
| 52-Week Range ($) | 0.82 - 11.32 | ||
| Shares Outstanding (Mil) | 36.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rain Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rain Oncology Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rain Oncology Inc Frequently Asked Questions
What is Rain Oncology Inc(RAIN)'s stock price today?
The current price of RAIN is $1.21. The 52 week high of RAIN is $11.32 and 52 week low is $0.82.
When is next earnings date of Rain Oncology Inc(RAIN)?
The next earnings date of Rain Oncology Inc(RAIN) is 2024-05-10 Est..
Does Rain Oncology Inc(RAIN) pay dividends? If so, how much?
Rain Oncology Inc(RAIN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers